Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
Cancers, March 2021
Ashley Hopkins, Ganessan Kichenadasse, Ahmad Abuhelwa, Ross McKinnon, Andrew Rowland, Michael Sorich
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
|Members of the public||3||75%|
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
|Readers by professional status||Count||As %|
|Student > Master||4||24%|
|Student > Bachelor||2||12%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||8||47%|
|Nursing and Health Professions||3||18%|
|Immunology and Microbiology||1||6%|
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2021.
All research outputs
of 23,292,144 outputs
Outputs from Cancers
of 13,206 outputs
Outputs of similar age
of 422,486 outputs
Outputs of similar age from Cancers
of 967 outputs
Altmetric has tracked 23,292,144 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 13,206 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,486 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 967 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.